BiotechTube

Zanidatamab + Tislelizumab + Trastuzumab + Capecitabine + Oxaliplatin + Cisplatin + 5-Fluorouracil

Phase 3Active
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastric Neoplasms

Conditions

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

Trial Timeline

Dec 2, 2021 → Jul 31, 2027

NCT ID
NCT05152147

About Zanidatamab + Tislelizumab + Trastuzumab + Capecitabine + Oxaliplatin + Cisplatin + 5-Fluorouracil

Zanidatamab + Tislelizumab + Trastuzumab + Capecitabine + Oxaliplatin + Cisplatin + 5-Fluorouracil is a phase 3 stage product being developed by BeOne Medicines for Gastric Neoplasms. The current trial status is active. This product is registered under clinical trial identifier NCT05152147. Target conditions include Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05152147Phase 3Active

Competing Products

20 competing products in Gastric Neoplasms

See all competitors
ProductCompanyStageHype Score
pemetrexed + cisplatinEli LillyPhase 1/2
41
InfigratinibLianBioPhase 2
44
InfigratinibLianBioPhase 2
44
Ramucirumab + MEDI4736Eli LillyPhase 1
33
RamucirumabEli LillyPhase 2
52
Trastuzumab + Capecitabine + CisplatinCelltrionPhase 2
52
Trastuzumab + Fluorouracil + Cisplatin + CapecitabineChugai PharmaceuticalPhase 3
77
Fluorouracil (5-FU) + Capecitabine + Durvalumab + Oxaliplatin + Trastuzumab + Trastuzumab deruxtecan + Cisplatin + Pembrolizumab + Volrustomig + RilvegostomigDaiichi SankyoPhase 2
52
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine CombinationDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + BevacizumabDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
23
DS-8201aDaiichi SankyoPhase 1
33
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Irinotecan + NimotuzumabDaiichi SankyoPhase 3
77
Trastuzumab Deruxtecan + pembrolizumab + Trastuzumab + ChemotherapyDaiichi SankyoPhase 3
77
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
41

Other Products from BeOne Medicines

ZanubrutinibApproved
82
Tislelizumab + Pamiparib + Temozolomide + Sitravatinib + Ociperlimab + BAT1706 + Fruquintinib + BGB-15025 + Zanidatamab + BGB-A445 + Surzebiclimab + Lenvatinib + LBL-007Phase 3
74
Zanubrutinib + Bendamustine + Rituximab + VenetoclaxPhase 3
74
Tislelizumab + Placebo + Cisplatin + Gemcitabine Hydrochloride + CarboplatinPhase 3
74
Sonrotoclax + Zanubrutinib + PlaceboPhase 3
74